Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946270 · ClinicalTrials.gov registry record · Phase 2
Pomalidomide for Myelofibrosis Patients
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT00946270: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00946270 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00946270, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
Interventions
- DRUG Prednisone
- DRUG CC-4047
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2009-07-22 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946270
The ClinicalTrials.gov registry entry for NCT00946270 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT00946270 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946270 about?
NCT00946270 is a clinical study titled "Pomalidomide for Myelofibrosis Patients". The goal of this clinical research study is to learn if CC-4047 (now called pomalidomide) and prednisone can help to control MMM. The safety of this therapy will also be studied.
What is the current status of trial NCT00946270?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2009-07-22. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT00946270?
The interventions under investigation include: Prednisone (DRUG), CC-4047 (DRUG).
Who is sponsoring clinical trial NCT00946270?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.